Search

Developmental defects affecting the heart and aortic arch arteries are a significant phenotype observed in 22q11 deletion syndrome patients and are caused by a microdeletion on chromosome 22q11. TBX1, one of the deleted genes, is expressed throughout the pharyngeal arches and is considered a key gene, when mutated, for the arch artery defects. Pax9 is expressed in the pharyngeal endoderm and is downregulated in Tbx1 mutant mice. We show here that Pax9 deficient mice are born with complex cardiovascular malformations affecting the outflow tract and aortic arch arteries with failure of the 3rd and 4th pharyngeal arch arteries to form correctly. Transcriptome analysis indicated that Pax9 and Tbx1 may function together, and mice double heterozygous for Tbx1/Pax9 presented with a significantly increased incidence of interrupted aortic arch when compared to Tbx1 heterozygous mice. Using a novel Pax9Cre allele we demonstrated that the site of this Tbx1-Pax9 genetic interaction is in the pharyngeal endoderm, therefore revealing that a Tbx1-Pax9-controlled signalling mechanism emanating from the pharyngeal endoderm is required for critical tissue interactions during normal morphogenesis of the pharyngeal arch artery system. [ABSTRACT FROM AUTHOR]

Background Phenobarbital is the first-line choice for neonatal seizures treatment, despite a response rate of approximately 45%. Failure to respond to acute anticonvulsants is associated with poor neurodevelopmental outcome, but knowledge on predictors of refractoriness is limited. Objective To quantify response rate to phenobarbital and to establish variables predictive of its lack of efficacy. Methods We retrospectively evaluated newborns with electrographically confirmed neonatal seizures admitted between January 1999 and December 2012 to the neonatal intensive care unit of Parma University Hospital (Italy), excluding neonates with status epilepticus. Response was categorized as complete (cessation of clinical and electrographic seizures after phenobarbital administration), partial (reduction but not cessation of electrographic seizures with the first bolus, response to the second bolus), or absent (no response after the second bolus). Multivariate analysis was used to identify independent predictors of refractoriness. Results Out of 91 newborns receiving phenobarbital, 57 (62.6%) responded completely, 15 (16.5%) partially, and 19 (20.9%) did not respond. Seizure type (p = 0.02), background electroencephalogram (EEG; p ≤ 0.005), and neurologic examination (p ≤ 0.005) correlated with response to phenobarbital. However, EEG (p < 0.02) and seizure type (p ≤ 0.001) were the only independent predictors. Conclusion Our results suggest a prominent role of neurophysiological variables (background EEG and electrographic-only seizure type) in predicting the absence of response to phenobarbital in high-risk newborns. [ABSTRACT FROM AUTHOR]

The skin lesions appeared around the leg ulcer and then spread within 3 weeks to both lower limbs, the upper limbs, and trunk, with nummular eczema-like aspects. Keywords: allergic contact dermatitis; case report; chloramphenicol; clostridiopeptidase A; collagenase I; leg ulcers; nummular eczema EN allergic contact dermatitis case report chloramphenicol clostridiopeptidase A collagenase I leg ulcers nummular eczema 122 123 2 01/20/22 20220201 NES 220201 Topical medications used for the treatment of venous leg ulcers are a well-known cause of allergic contact dermatitis (ACD).1 Among these, topical drugs containing proteolytic enzymes (used for wound debridement) are rarely involved.2,3 We herein report a case of severe ACD caused by clostridiopeptidase A, also known as collagenase I. CASE REPORT A nonatopic 64-year-old woman presented to our attention for the onset of a diffuse crusted eczematous dermatitis with nummular aspects (Figure 1). Allergic contact dermatitis, case report, chloramphenicol, clostridiopeptidase A, collagenase I, leg ulcers, nummular eczema. [Extracted from the article]

In vitro generated human cardiomyocytes hold the ultimate promise for heart patients for repair of injured or diseased myocardium, but they also provide experimental models for studying normal cardiomyocyte development, for disease modeling and for drug development. Here we provide reliable protocols for differentiation of human embryonic stem cells into functional cardiomyocytes, together with Notes about troubleshooting and optimizing such protocols for specific cell lines. This chapter also briefly discusses other published protocols and those further adapted for differentiation of induced pluripotent stem cells into cardiomyocytes.

In vitro generated mammalian cardiomyocytes provide experimental models for studying normal mammalian cardiomyocyte development, for disease modeling and for drug development. They also promise to inform future therapeutic strategies for repair of injured or diseased myocardium. Here we provide reliable protocols for differentiation of mouse embryonic stem cells into functional cardiomyocytes, together with Notes about trouble shooting and optimizing such protocols for specific cell lines.